You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Standardized Medicare/Medicaid Reimbursement for HCPP and other Small Payers

    SBC: Advanced Management Research            Topic: N/A

    N/A

    SBIR Phase II 1998 Department of Health and Human Services
  2. POCKET NEBULIZER

    SBC: Amnis Corporation            Topic: N/A

    BETA AGONISTS ADMINISTERED IN AEROSOL FORM IS ONE OF THE MOST POTENT AND WIDELY USED BRONCHODILATOR THERAPIES. IN HOSPITALS, BETA AGONISTS ARE USUALLY ADMINISTERED BY COMPRESSED AIR NEBULIZERS. NUMEROUS STUDIES HAVE DOCUMENTEDTHE EFFICACY OF THE BRONCHODILATOR AEROSOL DELIVERED FROM A CANISTER NEBULIZER, BUT THE MAJOR SHORTCOMING OF THIS FORM OF THERAPY IS THE POOR INHALATION TECHNIQUE OF SOME OF ...

    SBIR Phase II 1989 Department of Health and Human Services
  3. Small Molecule Therapeutics for Renal Disease

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic and non-diabetic nephropathies and the Metabolic Syndrome are associated with chronic kidney disease (CKD) - a program comprising proteinuria, accumulation of profibrotic collagen in the renal interstitium and relentless decline in renal function. CKD remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal d ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Neuroprotective/Restorative Therapy for Ischemic Stroke

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Ischemic Stroke continues to be a major cause of morbidity and mortality in the United States. Currently approved thrombolytic therapy suffers for a narrow therapeutic window and clearly other therapeutic strategies are needed, such as neuroprotective or restorative agents. Unfortunately the quest for a therapeutic remains beset by a history of failed clinical ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutic use of small-molecule HGF-mimetic for emphysema

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Emphysema is a major cause of death and disability and afflicts approximately 2 million people. The disease cost more than 2.5 billion in annual health care expenses and causes or contributes to the death of 100,000 people each year in the United States alone. The disease is characterized by destruction of the alveolar wall, permanent enlargement of the airspa ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Neuroprotective/Anti-inflammatory Therapy for Ischemic Stroke

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Stroke is leading cause of morbidity and mortality in the US. Research on the pathophysiological basis of stroke has produced new paradigms for prevention and treatment, but translation of these approaches into improved clinical outcomes has proved to be painfully slow. Preventive strategies focus primarily on reducing or controlling risk factors such as diabet ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Therapy for Amyotrophic Lateral Sclerosis

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Literature indicates that HGF via its cytoprotective and tissue-regenerative activities protects a number of organs against traumatic and/or ischemic injury and fibrotic/degenerative disease. We have evaluated the effects of Refanalin/BB3 in preclinical models of ischemic stroke, hepatic, renal, pulmonary and myocardial ischemia-reperfusion injury including mod ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Safety and PK Study in Hepatic Impairment Patients

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive alcohol use, iron overload or extrahepatic obstructions and can progress to liver cirrhosis, liver failure and death. In fact, deaths from complications of liver fibrosis/cirrhosis are expected to tr ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Pilot Clinical Study in Renal Transplantation

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Kidney transplantation is the most effective therapeutic modality for end-stage renal disease. Given the increasing demand for donor kidneys, more centers today are transplanting kidneys that were previously considered unsuitable. Extended donor kidneys include kidneys from non-heart-beating donors, aged donors, donors with mild-to-moderate hypertension, or kid ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Quality Assurance for Environmental Risks

    SBC: Applied Biomathematics Inc            Topic: N/A

    N/A

    SBIR Phase II 1998 Department of Health and Human Services
US Flag An Official Website of the United States Government